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Coronary heart disease (CHD) remains the leading cause of
death in the United States, and its foundational therapy, risk
factor control, remains problematic (1). Data from the
National Health and Nutrition Examination Survey suggest
that from 2005 to 2010, only 45% of United States patients
with hypercholesterolemia achieved low-density lipoprotein
(LDL) cholesterol control, and fewer than 1 in 3 patients
with hypertension and hypercholesterolemia attained control
of both disorders (2). These failures of treatment do not
appear to be due to lack of provider awareness, as most
physicians are cognizant of guideline-based goals; rather,
they can be largely ascribed to what has been called thera-
peutic inertia, which occurs when a provider fails to increaseSee page 2178therapy when treatment goals are unmet (3,4) (Table 1). In
uncontrolled hypertension, the prevalence of therapeutic
inertia is remarkably high, reported in 86.9% of visits when
the blood pressure was 140/90 mm Hg (5).
In addition to these prevalent but correctable impedi-
ments to achieving evidence-based goals, patients may less
commonly present with genetic disorders for which existing
therapies are genuinely insufﬁcient. In the case of lipid
management, patients with homozygous familial hypercho-
lesterolemia (HoFH) (frequency of 1 in 1 million) and se-
vere forms of heterozygous familial hypercholesterolemia
(frequency of 1 in 500) experience high rates of cardiovas-
cular morbidity and mortality, and conventional therapy
with statins, ezetimibe, newer bile acid sequestrants, and
extended-release niacin formations generally fail to achieve
LDL cholesterol levels anywhere near goal (6). Clearly,*Editorials published in the Journal of the American College of Cardiology reﬂect the
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with these unique genetic conditions.
To stimulate interest in meeting the needs of small
populations with rare diseases who have been “orphaned”
from pharmaceutical development because of poor economic
potential, Congress passed the Orphan Drug Act in 1983.
The legislation created ﬁnancial incentives in the form of
substantial tax incentives (totaling half the development
costs), clinical research and development subsides, fast-track
development and approval, and enhanced patent protection
and marketing rights for pharmaceutical manufacturers who
create drugs for Americans with a “rare disease or condition”
(7). These incentives were fashioned to kindle interest in
developing pharmaceutical agents when otherwise, there
would be “no reasonable expectation that the costs of drug
development and marketing would be recovered in future
sales of the drug in the United States,” and by most
measures, the Orphan Drug Act has been a successful
program to many of the 20 million to 25 million Americans
currently afﬂicted with rare diseases (7,8). To date, 425
indication designations covering 347 drugs have been
approved, and this success has led to the adoption of similar
orphan programs in Japan (1993) and the European Union
(2000) (9,10).
Thirty years after its passage, however, the political, social,
and economic context has evolved, and the orphan drug
market has transformed itself into a big business, currently
exceeding $61 billion in annual revenue, with projected
growth to $105 billion by 2017 (8,11). By 2018, orphan drugs
are expected to constitute 15.9% of worldwide prescription
sales, excluding generics, and today, the 5 most expensive
drugs in the world are orphan drugs, with price tags ranging
from $300,000 to $409,500 per year (Table 2) (10,12).
Because of such high prices, almost a third of all orphan drugs
marketed today will exceed $1 billion in annual sales (13).
A new orphan drug entering the cardiovascular arena is
mipomersen, a second-generation antisense oligonucleotide
developed for patients with HoFH. Given as a weekly
subcutaneous injection, mipomersen inhibits apolipoprotein
B-100 protein synthesis in the liver, leading to reductions in
apolipoprotein B–containing lipoproteins (including LDL
cholesterol) in the circulation. Phase 3 clinical trials con-
ducted in patients with HoFH and heterozygous familial
hypercholesterolemia on background statin therapy have
demonstrated reductions in LDL cholesterol of 25% to 28%
(14,15). Side effects reported include frequent injection site
reactions, ﬂu-like symptoms, increases in hepatic fat, and liver
function test abnormalities. On the basis of these ﬁndings, the
United States Food and Drug Administration approved
mipomersen in January 2013 (as a risk evaluation and miti-
gation strategy) as an adjunct to diet and drug therapy in
patients with HoFH, whereas its European counterpart, the
Committee for Medicinal Products for Human Use, recom-
mended against approval because of safety concerns (16,17).
In this issue of the Journal, Thomas et al. (18) evaluate the
use of mipomersen in 157 patients without a genetic disorder
Table 1 Factors Contributing to Therapeutic Inertia
Clinician Patient Health System
Failure to initiate treatment Medication side effects Lack of clinical guideline
Failure to titrate to goal Too many medications Lack of care coordination
Failure to set clear goals Cost of medications No visit planning
Underestimation of patient need Denial of disease Lack of decision support
Failure to identify and manage comorbid
conditions (such as depression)
Denial of disease severity Poor communication between
physician and ofﬁce staff
Insufﬁcient time Forgetfulness No disease registry
Insufﬁcient focus or emphasis on goal
attainment
Perception of low
susceptibility
No active outreach
Reactive rather than proactive Absence of disease
symptoms
Poor communication with
physician
Mistrust of clinician
Depression, mental illness,
substance abuse
Low health literacy
Modiﬁed from Allen et al. (4).
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2186of lipid metabolism but in whom CHD was established
or there was high risk for its development, who had not
met LDL cholesterol goals while on statin therapy
(mean LDL cholesterol 123 mg/dl). Interestingly, only
40% of patients were taking the maximal Food and
Drug Administration–approved statin dose, and only 57%
were taking second a lipid-lowering agent, thus mirroring
a level of therapeutic inertia commonly described in the
general population. After weekly injections over 26 weeks,
mipomersen-treated subjects demonstrated a reduction in
LDL cholesterol of 36.9% (with 76% falling below an
LDL cholesterol level of 100 mg/dl), compared with
placebo LDL cholesterol reductions of 4.5% (with 38%
falling below an LDL cholesterol level of 100 mg/dl).
Mipomersen treatment, however, was accompanied by a
high frequency of signiﬁcant side effects, including injection
site reactions, ﬂu-like symptoms, liver function test abnor-
malities, and hepatic steatosis, such that 43% of mipomersen-
treated subjects dropped out of the study. In contrast toTable 2
The Annual Cost of 2 New Lipid Agents in Comparison
With the 5 Most Expensive Drugs in the World
Drug Disease Annual Cost
Eculizumab (Soliris) Paroxysmal nocturnal
hemoglobinuria
$409,500
Idursulfase (Elaprase) Mucopolysaccharidosis II
(Hunter syndrome)
$375,000
Galsulfase (Naglazyme) Mucopolysaccharidosis VI
(Maroteaux-Larry syndrome)
$365,000
C1 esterase inhibitor
[human] (Cinryze)
Hereditary angioedema $350,000
Alglucosidase alfa
(Myozyme)
Pompe disease $300,000
Lomitapide (Juxtapid) Homozygous familial
hypercholesterolemia
$235,000–
$295,000
Mipomersen (Kynamro) Homozygous familial
hypercholesterolemia
$176,000patients with HoFH, among whom the dropout rate was 18%,
this therapy was judged unacceptable and intolerable in
a population of patients with a lower underlying disease
risk and in whom multiple less cumbersome treatment
alternatives are currently available (14). The investigators
conclude that clinicians should “focus on managing patient
expectations.” Rather, we should refocus our delivery
system to better manage and control health measures in
chronic disease. In hypertension, for which only half of
patients achieve goal blood pressures, reorganizing the
delivery model to include telemonitoring and pharmacist
intervention resulted in 71% of patients’ achieving blood
pressure control, compared with 53% using the existing
delivery model (19,20). For most patients with CHD or at
risk for CHD who do not have uncommon genetic dis-
orders, newer, more expensive and cumbersome pharma-
cotherapies should not be our ﬁrst priority, but rather
a reorganization of clinical practice to include nonphysician
practitioners.
For patients with HoFH, orphan drugs are clearly needed,
and in addition to mipomersen, a second orphan has been
recently approved by the Food and Drug Administration,
also as a risk evaluation and management strategy. Lomita-
pide is given once daily as oral therapy and has demonstrated
impressive reductions in LDL cholesterol (40% to 50%) in
patients with HoFH by inhibiting microsomal triglyceride
transfer protein; however, this was accompanied by side
effects including steatosis, gastrointestinal symptoms, and
liver function test abnormalities (21). The good news for
patients with HoFH is that both mipomersen and lomitapide
can offer the opportunity to lower LDL cholesterol closer to
goal, potentially reducing the substantial burden of disease
they have faced until now. Their collective ﬁnancial burden,
however, will be substantial: lomitapide runs $235,000 to
$295,000 a year, depending on the patient, and mipomersen
will cost $176,000 per year (13).
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2187These and other orphan drugs can offer hope to those
with an estimated 7,000 rare diseases that exist today (22).
The only question now will be if we can afford the bill.
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